Literature DB >> 14499768

Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study.

Massimo Conio1, Sabrina Blanchi, Gabriella Lapertosa, Roberto Ferraris, Renato Sablich, Santino Marchi, Vittorio D'Onofrio, Teresa Lacchin, Gaetano Iaquinto, Guido Missale, Paolo Ravelli, Renzo Cestari, Giorgio Benedetti, Giuseppe Macrì, Roberto Fiocca, Francesco Munizzi, Rosangela Filiberti.   

Abstract

OBJECTIVE: Barrett's esophagus (BE) is a premalignant condition for which regular endoscopic follow-up is usually advised. We evaluated the incidence of esophageal adenocarcinoma (AC) in patients with BE and the impact of endoscopic surveillance on mortality from AC.
METHODS: A cohort of newly diagnosed BE patients was studied prospectively. Endoscopic and histological surveillance was recommended every 2 yr. Follow-up status was determined from hospital and registry office records and telephone calls to the patients.
RESULTS: From 1987 to 1997, BE was diagnosed in 177 patients. We excluded three with high-grade dysplasia (HGD) at the time of enrollment. Follow-up was complete in 166 patients (135 male, 31 female). The mean length of endoscopic follow-up was 5.5 yr (range 0.5-13.3). Low-grade dysplasia (LGD) was present initially in 16 patients (9.6%) and found during follow-up in another 24 patients. However, in 75% of cases, LGD was not confirmed on later biopsies. HGD was found during surveillance in three patients (1.8%), one with simultaneous AC; two with HGD developed AC later. AC was detected in five male patients during surveillance. The incidence of AC was 1/220 (5/1100) patient-years of total follow-up, or 1/183.6 (5/918) patient-years in subjects undergoing endoscopy. Four AC patients died, and one was alive with advanced-stage tumor. The mean number of endoscopies performed for surveillance, rather than for symptoms, was 2.4 (range 1-10) per patient. During the follow-up years the cohort had a total of 528 examinations and more than 4000 biopsies.
CONCLUSIONS: The incidence of AC in BE is low, confirming recent data from the literature reporting an overestimation of cancer risk in these patients. In our patient cohort, surveillance involved a large expenditure of effort but did not prevent any cancer deaths. The benefit of surveillance remains uncertain.

Entities:  

Mesh:

Year:  2003        PMID: 14499768     DOI: 10.1111/j.1572-0241.2003.07666.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  62 in total

Review 1.  Early events during neoplastic progression in Barrett's esophagus.

Authors:  Brian J Reid
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

2.  Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements.

Authors:  Neil G Terry; Yizheng Zhu; Matthew T Rinehart; William J Brown; Steven C Gebhart; Stephanie Bright; Elizabeth Carretta; Courtney G Ziefle; Masoud Panjehpour; Joseph Galanko; Ryan D Madanick; Evan S Dellon; Dimitri Trembath; Ana Bennett; John R Goldblum; Bergein F Overholt; John T Woosley; Nicholas J Shaheen; Adam Wax
Journal:  Gastroenterology       Date:  2010-09-18       Impact factor: 22.682

3.  Evaluation of quantitative image analysis criteria for the high-resolution microendoscopic detection of neoplasia in Barrett's esophagus.

Authors:  Timothy J Muldoon; Nadhi Thekkek; Darren Roblyer; Dipen Maru; Noam Harpaz; Jonathan Potack; Sharmila Anandasabapathy; Rebecca Richards-Kortum
Journal:  J Biomed Opt       Date:  2010 Mar-Apr       Impact factor: 3.170

4.  Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves.

Authors:  Gary W Falk
Journal:  Dig Dis Sci       Date:  2010-07       Impact factor: 3.199

5.  Barrett's esophagus and the increasing role of endoluminal therapy.

Authors:  Michael S Smith; Charles J Lightdale
Journal:  Therap Adv Gastroenterol       Date:  2008-09       Impact factor: 4.409

6.  Are We Making Progress in Preventing Barrett's-Related Esophageal Cancer?

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

Review 7.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 8.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

9.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

10.  Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study.

Authors:  Mauro Rossi; Marco Barreca; Nicola de Bortoli; Cristina Renzi; Stefano Santi; Alessandro Gennai; Massimo Bellini; Francesco Costa; Massimo Conio; Santino Marchi
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.